• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SELICICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • SELICICLIB chembl:CHEMBL14762 Antineoplastic

    Alternate Names:

    NSC-701554
    SELICICLIB
    AL-39256
    CYC-202
    R-ROSCOVITINE
    ROSCOVITINE
    CYC202
    (2R)-2-((9-(1-METHYLETHYL)-6-((PHENYLMETHYL)AMINO)-9H-PURIN-2-YL)AMINO)-1-BUTANOL
    (2R)-2-{[6-(BENZYLAMINO)-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO}BUTAN-1-OL
    (R)-ROSCOVITINE
    (R)-2-((9-(1-METHYLETHYL)-6-((PHENYLMETHYL)AMINO)-9H-PURIN-2-YL)AMINO)-1-BUTANOL
    2-(R)-(1-ETHYL-2-HYDROXYETHYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE
    chemidplus:186692-46-6
    pubchem.compound:160355
    drugbank:06195
    chembl:CHEMBL14762

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Iurisci I et al., 2006, Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor., Cancer Res
    Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem
    Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem
    Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.
    Slovackova et al., 2012, Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53., Neoplasma
  • SELICICLIB   CCNB1

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21080703


    Sources:
    DTC

  • SELICICLIB   CCNA2

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21080703


    Sources:
    DTC

  • SELICICLIB   CDK7

    Interaction Score: 1.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Novel Target
    Trial Name seliciclib, R-roscovitine, CYC202
    Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

    PMIDs:
    17108108


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • SELICICLIB   CDK9

    Interaction Score: 0.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor
    Direct Interaction yes
    Trial Name seliciclib, R-roscovitine, CYC202

    PMIDs:
    17108108


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions

  • SELICICLIB   CDK2

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Novel Target
    Trial Name seliciclib, R-roscovitine, CYC202
    Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

    PMIDs:
    21080703 17108108


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • SELICICLIB   CCND1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21080703


    Sources:
    DTC

  • SELICICLIB   RB1

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21417417


    Sources:
    DTC

  • SELICICLIB   CDK1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor
    Direct Interaction yes

    PMIDs:
    17108108


    Sources:
    ChemblInteractions TTD

  • SELICICLIB   CDK5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SELICICLIB   TP53

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Preclinical - Cell culture

    PMIDs:
    21417417 26826118 22862161


    Sources:
    DTC JAX-CKB

  • SELICICLIB   SMN2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SELICICLIB   SMN1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: SELICICLIB

    • Version: 20-Jun-2017

    Alternate Names:
    CYC202 Development Name
    SELICICLIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: SELICICLIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • DTC: SELICICLIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL14762 ChEMBL Drug ID

    Drug Info:

    Publications:
    Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem
    Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem

  • JAX-CKB: Seliciclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Slovackova et al., 2012, Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53., Neoplasma
    Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.

  • TTD: R-roscovitine

    • Version: 2020.06.01

    Alternate Names:
    D05ADP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL14762

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL14762

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21